XML 29 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Unaudited Statements of Operations - USD ($)
3 Months Ended 6 Months Ended
Jul. 31, 2020
Jul. 31, 2019
Jul. 31, 2020
Jul. 31, 2019
Revenue:        
Revenues $ 35,009,000 $ 30,817,000 $ 68,405,000 $ 59,126,000
Expenses:        
Cost of revenue (excluding depreciation and amortization) 5,271,000 4,210,000 10,005,000 8,206,000
Payment processing expense 6,747,000 7,101,000 13,595,000 14,050,000
Sales and marketing 10,098,000 8,120,000 19,532,000 15,822,000
Research and development 5,530,000 4,690,000 10,535,000 8,989,000
General and administrative 9,631,000 7,421,000 18,351,000 13,665,000
Depreciation 2,410,000 2,136,000 4,678,000 4,291,000
Amortization 1,632,000 1,279,000 2,985,000 2,498,000
Total expenses 41,319,000 34,957,000 79,681,000 67,521,000
Operating loss (6,310,000) (4,140,000) (11,276,000) (8,395,000)
Other income (expense) 424,000 327,000 (291,000) (818,000)
Change in fair value of warrant liability 0 (2,884,000) 0 (3,307,000)
Interest income (expense) (419,000) (745,000) (739,000) (1,549,000)
Total other income (expense) 5,000 (3,302,000) (1,030,000) (5,674,000)
Loss before provision for income taxes (6,305,000) (7,442,000) (12,306,000) (14,069,000)
Provision for income taxes (66,000) (51,000) (177,000) (119,000)
Net loss (6,371,000) (7,493,000) (12,483,000) (14,188,000)
Preferred stock dividend paid 0 (14,955,000) 0 (14,955,000)
Accretion of redeemable preferred stock 0 (48,312,000) 0 (56,175,000)
Net loss attributable to common stockholders, basic and diluted $ (6,371,000) $ (70,760,000) $ (12,483,000) $ (85,318,000)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) $ (0.17) $ (10.42) $ (0.33) $ (19.20)
Weighted-average common shares outstanding, basic and diluted (in shares) 37,735,155 6,793,363 37,523,966 4,443,155
Subscription and related services        
Revenue:        
Revenues $ 17,129,000 $ 14,004,000 $ 32,728,000 $ 26,686,000
Payment processing fees        
Revenue:        
Revenue from contract with customer 11,828,000 11,665,000 23,535,000 23,222,000
Life sciences        
Revenue:        
Revenue from contract with customer $ 6,052,000 $ 5,148,000 $ 12,142,000 $ 9,218,000